The immunogenicity of the ChAdOx1 nCoV-19 vaccination in participants with underlying comorbidity diseases: A prospective cohort study

References

• WHO. Coronavirus disease (COVID-19). 2022. https://www.who.int/health-topics/coronavirus#tab=tab_1.
   Google Scholar
• Cao Y, Hiyoshi A, Montgomery S. COVID-19 case-fatality rate and demographic and socioeconomic influencers: worldwide spatial regression analysis based on country-level data. BMJ Open. 2020;10(11):e043560. doi:10.1136/bmjopen-2020-043560.
   PubMed Web of Science ®Google Scholar
• Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239–11. doi:10.1001/jama.2020.2648.
   PubMed Web of Science ®Google Scholar
• Dessie ZG, Zewotir T. Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. BMC Infect Dis. 2021;21(1):855. doi:10.1186/s12879-021-06536-3.
   PubMed Web of Science ®Google Scholar
• Pagano L, Salmanton-Garcia J, Marchesi F, Busca A, Corradini P, Hoenigl M, Klimko N, Koehler P, Pagliuca A, Passamonti F, et al. COVID-19 infection in adult patients with hematological malignancies: a European hematology association survey (EPICOVIDEHA). J Hematol Oncol. 2021;14(1):168. doi:10.1186/s13045-021-01177-0.
   PubMed Web of Science ®Google Scholar
• Chavez-MacGregor M, Lei X, Zhao H, Scheet P, Giordano SH. Evaluation of COVID-19 mortality and adverse outcomes in US patients with or without cancer. JAMA Oncol. 2022;8(1):69–78. doi:10.1001/jamaoncol.2021.5148.
   PubMed Web of Science ®Google Scholar
• Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, Curtis HJ, Mehrkar A, Evans D, Inglesby P, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430–6. doi:10.1038/s41586-020-2521-4.
   PubMed Web of Science ®Google Scholar
• Rahmani A, Dini G, Leso V, Montecucco A, Kusznir Vitturi B, Iavicoli I, Durando P. Duration of SARS-CoV-2 shedding and infectivity in the working age population: a systematic review and meta-analysis. Med Lav. 2022;113(2):e2022014. doi:10.23749/mdl.v113i2.12724.
   PubMed Web of Science ®Google Scholar
• Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat Rev Immunol. 2021;21(8):475–84. doi:10.1038/s41577-021-00578-z.
   PubMed Web of Science ®Google Scholar
• Falsey AR, Sobieszczyk ME, Hirsch I, Sproule S, Robb ML, Corey L, Neuzil KM, Hahn W, Hunt J, Mulligan MJ, et al. Phase 3 safety and efficacy of AZD1222 (ChAdox1 nCoV-19) covid-19 vaccine. N Engl J Med. 2021;385(25):2348–60. doi:10.1056/NEJMoa2105290.
   PubMed Web of Science ®Google Scholar
• Sritipsukho P, Khawcharoenporn T, Siribumrungwong B, Damronglerd P, Suwantarat N, Satdhabudha A, Chaiyakulsil C, Sinlapamongkolkul P, Tangsathapornpong A, Bunjoungmanee P, et al. Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study. Emerg Microbes Infect. 2022;11(1):585–92. doi:10.1080/22221751.2022.2037398.
   PubMed Web of Science ®Google Scholar
• Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, Dold C, Fuskova M, Gilbert SC, Hirsch I, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med. 2021;27(11):2032–40. doi:10.1038/s41591-021-01540-1.
   PubMed Web of Science ®Google Scholar
• Rincon-Arevalo H, Choi M, Stefanski AL, Halleck F, Weber U, Szelinski F, Jahrsdörfer B, Schrezenmeier H, Ludwig C, Sattler A, et al. Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. Sci Immunol. 2021;6(60):eabj1031. doi:10.1126/sciimmunol.abj1031.
   PubMed Web of Science ®Google Scholar
• Kristiansen PA, Page M, Bernasconi V, Mattiuzzo G, Dull P, Makar K, Plotkin S, Knezevic I. WHO International standard for anti-SARS-CoV-2 immunoglobulin. Lancet. 2021;397(10282):1347–8. doi:10.1016/S0140-6736(21)00527-4.
   PubMed Web of Science ®Google Scholar
• Fu J, Shen X, Anderson M, Stec M, Petratos T, Cloherty G, Montefiori DC, Landay A, Moy JN. Correlation of binding and neutralizing antibodies against SARS-CoV-2 omicron variant in infection-naïve and convalescent BNT162b2 recipients. Vaccines (Basel). 2022;10(11):1904. doi:10.3390/vaccines10111904.
   PubMed Web of Science ®Google Scholar
• Resman Rus K, Korva M, Knap N, Avsic Zupanc T, Poljak M. Performance of the rapid high-throughput automated electrochemiluminescence immunoassay targeting total antibodies to the SARS-CoV-2 spike protein receptor binding domain in comparison to the neutralization assay. J Clin Virol. 2021;139:104820. doi:10.1016/j.jcv.2021.104820.
   PubMed Web of Science ®Google Scholar
• Hoque A, Barshan AD, Chowdhury FUH, Fardous J, Hasan MJ, Khan MAS, Kabir A. Antibody response to ChAdOx1-nCoV-19 vaccine among recipients in Bangladesh: a prospective observational study. Infect Drug Resist. 2021;14:5491–500. doi:10.2147/IDR.S335414.
   PubMed Web of Science ®Google Scholar
• Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA, Davenport MP, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–11. doi:10.1038/s41591-021-01377-8.
   PubMed Web of Science ®Google Scholar
• Fendler A, Shepherd STC, Au L, Wilkinson KA, Wu M, Byrne F, Rzeniewicz K, Gordon W, Shum B, Gerard CL, et al. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. Nat Cancer. 2021;2(12):1321–37. doi:10.1038/s43018-021-00275-9.
   Google Scholar
• Ligumsky H, Safadi E, Etan T, Vaknin N, Waller M, Croll A, Nikolaevski-Berlin A, Greenberg I, Halperin T, Wasserman A, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine among actively treated cancer patients. J Natl Cancer Inst. 2022;114(2):203–9. doi:10.1093/jnci/djab174.
   PubMedGoogle Scholar
• Lim SH, Stuart B, Joseph-Pietras D, Johnson M, Campbell N, Kelly A, Jeffrey D, Turaj AH, Rolfvondenbaumen K, Galloway C, et al. Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study. Nat Cancer. 2022;3(5):552–64. doi:10.1038/s43018-022-00364-3.
   PubMedGoogle Scholar
• Maneikis K, Sablauskas K, Ringeleviciute U, Vaitekenaite V, Cekauskiene R, Kryzauskaite L, Naumovas D, Banys V, Pečeliūnas V, Beinortas T, et al. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Lancet Haematol. 2021;8(8):e583–e92. doi:10.1016/S2352-3026(21)00169-1.
   PubMed Web of Science ®Google Scholar
• Teeyapun N, Luangdilok S, Pakvisal N, Sainamthip P, Mingmalairak S, Poovorawan N, Sitthideatphaiboon P, Parinyanitikul N, Sriuranpong V, Namkanisorn T, et al. Immunogenicity of ChAdOx1-nCoV-19 vaccine in solid malignancy patients by treatment regimen versus healthy controls: a prospective, multicenter observational study. EClinicalMedicine. 2022;52:101608. doi:10.1016/j.eclinm.2022.101608.
   PubMedGoogle Scholar
• Vink P, Delgado Mingorance I, Maximiano Alonso C, Rubio-Viqueira B, Jung KH, Rodriguez Moreno JF, Grande E, Marrupe Gonzalez D, Lowndes S, Puente J, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: a randomized trial. Cancer. 2019;125(8):1301–12. doi:10.1002/cncr.31909.
   PubMed Web of Science ®Google Scholar
• Wu JT, La J, Branch-Elliman W, Huhmann LB, Han SS, Parmigiani G, Tuck DP, Brophy MT, Do NV, Lin AY, et al. Association of COVID-19 vaccination with SARS-CoV-2 infection in patients with cancer: a US nationwide veterans affairs study. JAMA Oncol. 2022;8(2):281–6. doi:10.1001/jamaoncol.2021.5771.
   PubMed Web of Science ®Google Scholar
• Rotterdam J, Thiaucourt M, Weiss C, Schwaab J, Reiter A, Kreil S, Steiner L, Fenchel S, Popp HD, Hofmann W-K, et al. Definition of factors associated with negative antibody response after COVID-19 vaccination in patients with hematological diseases. Ann Hematol. 2022;101(8):1825–34. doi:10.1007/s00277-022-04866-z.
   PubMed Web of Science ®Google Scholar
• Sourij C, Tripolt NJ, Aziz F, Aberer F, Forstner P, Obermayer AM, Kojzar H, Kleinhappl B, Pferschy PN, Mader JK, et al. Humoral immune response to COVID-19 vaccination in diabetes is age-dependent but independent of type of diabetes and glycaemic control: the prospective COVAC-DM cohort study. Diabetes Obes Metab. 2022;24(5):849–58. doi:10.1111/dom.14643.
   PubMed Web of Science ®Google Scholar
• Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, Voysey M, Aley PK, Angus B, Babbage G, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021;396(10267):1979–93. doi:10.1016/S0140-6736(20)32466-1.
   PubMed Web of Science ®Google Scholar
• Tawinprai K, Siripongboonsitti T, Porntharukchareon T, Dechates B, Monprach H, Sornsamdang G, Wittayasak K, Soonklang K, Mahanonda N. Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population. Hum Vaccin Immunother. 2022;18(1):2035573. doi:10.1080/21645515.2022.2035573.
   PubMed Web of Science ®Google Scholar
• Sanders JF, Bemelman FJ, Messchendorp AL, Baan CC, van Baarle D, van Binnendijk R, Diavatopoulos DA, Frölke SC, Geers D, GeurtsvanKessel CH, et al. The RECOVAC immune-response study: the immunogenicity, tolerability, and safety of COVID-19 vaccination in patients with chronic kidney disease, on dialysis, or living with a kidney transplant. Transplantation. 2022;106(4):821–34. doi:10.1097/TP.0000000000003983.
   PubMed Web of Science ®Google Scholar
• Ruether DF, Schaub GM, Duengelhoef PM, Haag F, Brehm TT, Fathi A, Wehmeyer M, Jahnke-Triankowski J, Mayer L, Hoffmann A, et al. SARS-CoV2-specific humoral and T-cell immune response after second vaccination in liver cirrhosis and transplant patients. Clin Gastroenterol Hepatol. 2022;20(1):162–72 e9. doi:10.1016/j.cgh.2021.09.003.
   PubMed Web of Science ®Google Scholar
• Boekel L, Steenhuis M, Hooijberg F, Besten YR, van Kempen ZLE, Kummer LY, van Dam KPJ, Stalman EW, Vogelzang EH, Cristianawati O, et al. Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies. Lancet Rheumatol. 2021;3(11):e778–e88. doi:10.1016/S2665-9913(21)00222-8.
   PubMedGoogle Scholar
• Furer V, Eviatar T, Zisman D, Peleg H, Paran D, Levartovsky D, Zisapel M, Elalouf O, Kaufman I, Meidan R, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis. 2021;80(10):1330–8. doi:10.1136/annrheumdis-2021-220647. Epub 2021 Jun 14. Erratum in: Ann Rheum Dis. 2022 Jul;81(7):e133.
   PubMed Web of Science ®Google Scholar
• Butsch WS, Hajduk A, Cardel MI, Donahoo WT, Kyle TK, Stanford FC, Zeltser LM, Kotz CM, Jastreboff AM. COVID-19 vaccines are effective in people with obesity: a position statement from the obesity society. Obesity (Silver Spring). 2021;29(10):1575–9. doi:10.1002/oby.23251.
   PubMed Web of Science ®Google Scholar
• Piernas C, Patone M, Astbury NM, Gao M, Sheikh A, Khunti K, Shankar-Hari M, Dixon S, Coupland C, Aveyard P, et al. Associations of BMI with COVID-19 vaccine uptake, vaccine effectiveness, and risk of severe COVID-19 outcomes after vaccination in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2022;10(8):571–80. doi:10.1016/S2213-8587(22)00158-9.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15. doi:10.1056/NEJMoa2034577.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–16. doi:10.1056/NEJMoa2035389.
   PubMed Web of Science ®Google Scholar
• Naruse H, Ito H, Izawa H, Sarai M, Ishii J, Sakaguchi E, Murakami R, Ando T, Fujigaki H, Saito K, et al. Immunogenicity of BNT162b2 mRNA COVID-19 vaccine in patients with cardiovascular disease. J Clin Med. 2021;10(23):5498. doi:10.3390/jcm10235498.
   PubMed Web of Science ®Google Scholar
• Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Oxford COVID Vaccine Trial Group, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397(10277):881–91. doi:10.1016/S0140-6736(21)00432-3.
   PubMed Web of Science ®Google Scholar
• Mehta P, Paul A, Ahmed S, Cherian S, Panthak A, Benny J, Shenoy P. Effectiveness of delayed second dose of AZD1222 vaccine in patients with autoimmune rheumatic disease. Clin Rheumatol. 2022;41(11):3537–42. doi:10.1007/s10067-022-06247-3.
   PubMed Web of Science ®Google Scholar
• Goel A, Verma A, Tiwari P, Katiyar H, Aggarwal A, Khetan D, Mayank, Kishore RVK, Kumar P, Singh TP, et al. Serological immune response following ChAdOx1 nCoV-19 vaccine (covishield®) in patients with liver cirrhosis. Vaccines (Basel). 2022;10(11):1837. doi:10.3390/vaccines10111837.
   PubMed Web of Science ®Google Scholar
• Marfella R, D’Onofrio N, Sardu C, Scisciola L, Maggi P, Coppola N, Romano C, Messina V, Turriziani F, Siniscalchi M, et al. Does poor glycaemic control affect the immunogenicity of the COVID-19 vaccination in patients with type 2 diabetes: the CAVEAT study. Diabetes Obes Metab. 2022;24(1):160–5. doi:10.1111/dom.14547.
   PubMed Web of Science ®Google Scholar